Reassessment of cardiovascular risk in diabetes

Current Opinion in Lipidology

Volumn 17, Issue 6, 2006, Pages 644-652

  Jaffe, Jonathan R ^a   Nag, Soma S ^a   Landsman, Pamela B ^a   Alexander, Charles M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cholesterol; Diabetes; Hypertension; Risk

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATEGLINIDE; PIOGLITAZONE; RAMIPRIL; ROSIGLITAZONE; ROSUVASTATIN; VALSARTAN;

ACUTE HEART INFARCTION; AMINOTRANSFERASE BLOOD LEVEL; ANGIOCARDIOGRAPHY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES CONTROL; DIABETIC MICROANGIOPATHY; DIABETIC PATIENT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SIDE EFFECT; STABLE ANGINA PECTORIS; THORAX PAIN; UNSTABLE ANGINA PECTORIS;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERTENSION; LIPIDS; RISK FACTORS;

EID: 33750902424     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3280106208     Document Type: Review

References (39)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-444.
2. Ho JE, Paultre F, Mosca L. Is diabetes a cardiovascular risk equivalent for fatal stroke in women? Data from the Women's Pooling Project. Stroke 2003; 34:2812-2816.
3. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
4. Whiteley L, Padmanabhan S, Hole D, Isles C. Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of follow-up in the Renfrew and Paisley Survey. Diabetes Care 2005; 28:1588-1593.
5. Juutilainen A, Lehto S, Ronnemaa T, et al. Type 2 diabetes as a 'coronary heart equivalent': an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005; 28:2901-2907.
6. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414:782-787.
7. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20:614-620.
8. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial: The CARE Investigators. Circulation 1998; 98:2513-2519.
9. Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26:2713-2721.
10. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-2016.
11. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158.
12. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685-696.
13. Waters DD, Guyton JR, Herrington DM, et al. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004; 93:154-158.
14. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435. This study, which includes over 10 000 patients, provides additional evidence for intensive statin therapy to lower LDL cholesterol to below currently recommended levels among patients with stable CHD.
15. Shepherd J, Barter P, Carmena R, et al. Treating to New Targets (TNT) Study: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. Diabetes Care 2006; 29:1220-1226. This substudy of the TNT study, which includes over 1500 patients, provides additional evidence for intensive statin therapy to lower LDL cholesterol to below currently recommended levels among patients with stable CHD and diabetes.
16. Knopp RH, D'Emden M, Smilde JG, Pocock SJ, for the ASPEN Study Group. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes. Diabetes Care 2006; 29:1478-1485. This is one of the few studies focused exclusively on impact of statin treatment in patients with type 2 diabetes.
17. American Diabetes Association. Standards of medical care in diabetes (Position Statement). Diabetes Care 2006; 29 (Suppl. 1): S4-S39.
18. Nissen SE, Nicholls SJ, Sipahi I, et al., for the ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. J Am Med Assoc 2006; 295:1556-1565. This is the first study to demonstrate that very intensive statin therapy to lower LDL cholesterol well below currently accepted guidelines can actually cause regression of atherosclerosis measured by IVUS imaging in patients with coronary disease.
19. Keech A, Simes RJ, Barter P, et al., FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-1861. This study included almost 10 000 diabetic subjects and did not demonstrate that a fibrate (i.e. fenofibrate) significantly reduced the primary endpoint of myocardial infarction and CHD death. Importantly, however, the results were confounded by the significant off-trial use of statins.
20. Action to Control Cardiovascular Risk in Diabetes (ACCORD). ACCORD Purpose. 2006. http://www.accordtrial.org [Accessed: 5 September 2006].
21. Malmberg K, Ryden L, Efendic S, et al., for the DIGAMI study group. A randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction: Effects on mortality at 1 year. J Am Coll Cardiol 1995; 26:57-65.
22. Malmberg K. Prospective randomized study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. Br Med J 1997; 314:1512-1515.
23. Malmberg K, Ryden L, Wedel H, et al., Waldenstrom for the DIGAMI-2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI-2): effects on mortality and morbidity. Eur Heart J 2005; 26:650-661.
24. Goyal A, Mahaffey KW, Garg J, et al. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J 2006; 27:1289-1297. This study showed that failure of glucose levels to decrease in the first day after myocardial infarction predicted higher mortality in nondiabetic patients.
25. Zerr KJ, Furnary AP, Grunkemeier GL, et al. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 1997; 63:356-361.
26. Zerr KJ, Furnary AP, Grunkemeier GL, et al. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 1997; 63:356-361.
27. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367.
28. Dormandy JA, Charbonnel B, Eckland DJ, et al., PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289. PROACTIVE showed benefit of pioglitazone treatment on cardiovascular events with offsetting risk of increased heart failure. Whether statin treated patients receive any cardiovascular benefit from a glitazone or other PPAR remains to be determined.
29. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342:381-389. [Erratum, N Engl J Med 2000; 342:1376].
30. Nathan DM, Cleary PA, Backlund JY, et al., Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653. This very important epidemiologic observational long-term study looks at the outcomes of intensive glycemic control over time and shows the long-term benefits of glycemic control on cardiovascular outcomes.
31. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
32. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications inpatients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
33. Stratton IM, Cull CA, Adler AI, et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006; 49:1761-1769. This study demonstrated that simultaneously treating diabetic patients for both elevated glucose and blood pressure results in better outcomes in an additive manner reducing the risk of diabetic complications.
34. The NAVIGATOR Trial Investigators. Nateglinide and valsartan in impaired glucose tolerance outcomes research: rational and design of the NAVIGATOR trial. Diabetes 2002; 51 (Suppl. 2): A116 [abstract].
35. The DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004; 47:1519-1527.
36. Clarke PM, Gray AM, Briggs A, et al., on behalf of the UK Prospective Diabetes Study (UKPDS) Group. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004; 47:1747-1759.
37. National Center for Health Statistics. Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-1994. Hyattsville, MD: National Center for Health Statistics; 1994 (Vital and Health Statistics Series 1, no. 32).
38. Alexander CM, Landsman PB, Teutsch SM, Haffner SM, Third National Health and Nutrition Examination Survey (NHANES III). National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52:1210-1214.
39. Zgibor JC, Piatt GA, Ruppert K, et al. Deficiencies of cardiovascular risk prediction models for type 1 diabetes. Diabetes Care 2006; 29:1860-1865.